IX001 TCR-T / Shanghai Bintie Biotech - LARVOL DELTA

IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Shanghai Pudong Hospital | N=12 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Sun Yat-sen University | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Pancreatic Cancer • Solid Tumor

A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Sun Yat-sen University

New P1 trial • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

The clinical trial application of IX001 TCR-T injection of Bintie Biotech in China has been accepted for pancreatic cancer [Google translation] (myimm.net) - "On July 12, the Drug Review Center of the National Medical Products Administration showed that the clinical trial application for IX001 TCR-T injection submitted by Bintie Biopharma has been accepted. IX001 TCR-T injection is a TCR-T cell therapy targeting KRAS G12V mutation and is used to treat pancreatic cancer."

Trial status • Pancreatic Cancer

IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Shanghai Pudong Hospital

Metastases • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor